Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

Mesiano, Giulia; Todorovic, Maja; Gammaitoni, Loretta; Leuci, Valeria; Giraudo, Lidia; Carnevale-Schianca, Fabrizio; Fagioli, Franca; Piacibello, Wanda; Aglietta, Massimo; Sangiolo, Dario

doi:10.1517/14712598.2012.675323

Cited by 131 publications

(102 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIK cells mediate both specific MHC-restricted recognition and non-MHC-restricted cytotoxicity against target cells. [2][3][4][5][6] The activating NK cell receptor, NKG2D, has a crucial role in binding and cytolytic activity of CIK cells against tumor cells expressing the corresponding ligands. 2,3 The best characterized ligands for NKG2D are relatively restricted to tumor cells.…”

Section: Total Number Of Cellsmentioning

confidence: 99%

Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation

Rettinger

Bönig

Wehner

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Haploidentical hematopoietic SCT is an established treatment for high-risk leukemia in patients lacking a HLA-identical donor, and is also being evaluated for refractory solid tumors.The therapeutic success of any SCT for malignant disease is limited by relapse. Impending relapse can be treated by DLI, but DLI is of limited value when initiated during overt relapse. 1 Moreover, the high T-cell doses required for DLI pose a risk of severe GVHD, specifically in the haploidentical setting.

show abstract

Section: Total Number Of Cellsmentioning

confidence: 99%

Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation

Rettinger

Bönig

Wehner

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…3,[22][23][24][25][26] Several reviews and meta-analysis reports have also demonstrated the safety and effectiveness of adjuvant CIT in clinics. [27][28][29][30] However, the patterns of CIT require thorough investigation in order to achieve optimal outcome and cost-effectiveness.…”

Section: Introductionmentioning

confidence: 99%

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Postoperative non-small cell lung cancer (NSCLC) patients require adjuvant therapy to improve their prognosis. In this study, we investigated the efficacy of a sequential combination of autologous cellular immunotherapy (CIT) and chemotherapy for postoperative NSCLC. This retrospective study included 120 postoperative NSCLC patients: 60 cases received only chemotherapy; 33 cases received chemotherapy and sequential CIT with cytokine-induced killer (CIK) cells; and 27 cases received chemotherapy and sequential CIT with alternate CIK and natural killer (NK) cells. Survival analysis showed significantly higher overall survival rates in the CIT group compared with the control group. Overall survival was higher in patients who received CIT with alternate CIK and NK cells than those who received treatment with only CIK cells. Multivariate analysis showed that adjuvant CIT was an independent prognostic factor for overall survival of patients with NSCLC. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients with less than 60 y old and positive lymph node. In conclusions, these data indicate that adjuvant CIT, especially with alternate application of CIK and NK cells, is an effective therapeutic approach to prolong survival of patients with NSCLC, particularly for patients 60 y old with positive lymph nodes.

show abstract

“…Proofs of antitumor activities were clearly provided but the clinical responses were much lower than expected (Mesiano et al, 2012).…”

Section: Discussionmentioning

confidence: 91%

Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin

Chen

Xiang

Ding

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: The aim of our study is to observe the impact of cholangiocarcinoma-derived exosomes on the antitumor activities of cytokine-induced killer (CIK) cells and then demonstrate the appropriate mechanism. Methods: Tumor-derived exosomes (TEXs), which are derived from RBE cells (human cholangiocarcinoma line), were collected by ultracentrifugation. CIK cells induced from peripheral blood were stimulated by TEXs. Fluorescence-activated cell sorting (FACS) was performed to determine the phenotypes of TEX-CIK and N-CIK (normal CIK) cells. The concentrations of tumor necrosis factor-α (TNF-α) and perforin in the culture medium supernatant were examined by using an enzyme-linked immunosorbent assay (ELISA) kit. A CCK-8 kit was used to evaluate the cytotoxic activity of the CIK cells to the RBE cell line. Results: The concentrations of TNF-α and perforin of the group TEX-CIK were 138.61 pg/ml and 2.41 ng/ml, respectively, lower than those of the group N-CIK 194.08 pg/ml (P<0.01) and 3.39 ng/ml (P<0.05). The killing rate of the group TEX-CIK was 33.35%, lower than that of the group N-CIK (47.35% (P<0.01)). The population of CD3

show abstract

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

Cited by 131 publications

References 74 publications

Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation

Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin

Contact Info

Product

Resources

About